nab-sirolimus + anastrozole

nab-sirolimus + anastrozole is a **combination therapy** under investigation for cancer indications, especially hormone-driven tumors. nab-sirolimus is a nanoparticle albumin-bound formulation of sirolimus, a potent mTOR inhibitor; anastrozole is an aromatase inhibitor that blocks estrogen synthesis. Combination aims to enhance antitumor effects and overcome resistance mechanisms in hormone-driven cancers by dual inhibition of the mTOR pathway and estrogen signaling. Both agents have demonstrated combinability in nonclinical studies and clinical trials; nab-sirolimus is developed by Aadi Bioscience for mTOR pathway–altered cancers, and anastrozole is a widely used, generic aromatase inhibitor for hormone-driven breast and gynecological cancers[1][5][6]. The combination is being clinically explored in settings such as endometrial cancer, due to potential synergy in targeting resistance and improving efficacy.

Other names

nanoparticle albumin-bound sirolimus + anastrozole